Table 2. Adjusted odds ratios for anti-N seroprevalence in various time periods following a positive SARS-CoV-2 viral test result by immunocompromising conditions (IC)—United States, July 2020–February 2022.
| Adjusted Odds Ratios* | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14–90 days | 91–180 days | 181–365 days | 365+ days | |||||||||
| IC status, prior 5 years | OR | LL | UL | OR | LL | UL | OR | LL | UL | OR | LL | UL |
| No IC | reference | reference | reference | reference | ||||||||
| Any IC | 0.61 | 0.40 | 0.93 | 0.81 | 0.52 | 1.25 | 1.00 | 0.74 | 1.37 | 1.00 | 0.73 | 1.38 |
| Solid malignancy | 0.03 | 0.00 | 0.51 | 0.50 | 0.11 | 2.30 | 0.42 | 0.10 | 1.80 | 1.33 | 0.47 | 3.80 |
| ICD10 codes: C00–C80, C7A, C7B, D3A, Z51.0, Z51.1 | ||||||||||||
| Hematologic malignancy | 0.42 | 0.09 | 1.98 | 0.64 | 0.11 | 3.86 | 2.36 | 0.68 | 8.13 | 0.88 | 0.29 | 2.69 |
| ICD10 codes: C81–C86, C88, C90–C96, D46, D61.0, D70.0, D61.2, D61.9, D71 | ||||||||||||
| Rheumatologic or inflammatory disorder | 0.67 | 0.40 | 1.11 | 0.78 | 0.46 | 1.32 | 1.00 | 0.70 | 1.43 | 0.97 | 0.66 | 1.40 |
| ICD10 codes: D86, E85 [except E85.0], G35, J67.9, L40.54, L40.59, L93.0, L93.2, L94, M05–M08, M30, M31.3, M31.5, M32–M34, M35.3, M35.8, M35.9, M46, T78.40 | ||||||||||||
| Organ or stem cell transplant | - | - | - | - | ||||||||
| ICD10 codes: T86 [except T86.82–T86.84, T86.89, and T86.9], D47.Z1, Z48.2, Z94, Z98.85 | ||||||||||||
| Other intrinsic immune condition | 0.52 | 0.27 | 0.97 | 0.75 | 0.36 | 1.54 | 1.01 | 0.61 | 1.67 | 1.05 | 0.64 | 1.74 |
| ICD10 codes: D27.9, D61.09, D72.89, D80, D81 [except D81.3], D82–D84, D89 [except D89.2], K70.3, K70.4, K72, K74.3–K74.6 [except K74.60 and K74.69], N04, R18 | ||||||||||||
OR = Odds Ratio, LL = Lower limit of 99% Confidence interval, UL = Upper limit of 99% Confidence interval,— = results excluded due to imprecise estimates, shaded cells indicate statistical significance at 99% confidence
*adjusted for age, sex, metro status, and SVI tertile